Effectiveness and costs of an individualized therapy for the treatment of cytostatic-induced emesis;Effektivität und Kosten einer individualisierten antiemetischen Prophylaxe bei Zytostatikatherapie

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 5, 2009, Pages 401-405

  Rosenhahn, A ^a   Camara, O ^a   Runnebaum, I B ^a   Fix, P ^a   Hartmann, M ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Costeffectiveness; Cytostaticinduced emesis; Individualized antiemetic prophylaxis

Indexed keywords

CYTOSTATIC AGENT;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOMITING;

EID: 77149134354     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1185632     Document Type: Article

References (15)

1. de Boer-Dennert M, de Wit R, Schmitz PI et al. Patients perception of side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997; 76: 1055-1061
2. Regidor PA, Schindler AE. Granisetron, ein neues und potentes Antiemetikum zur Behandlung der zytostatikainduzierten Emesis gynäkologischer Malignome. Geburts Frauenheilk 1994; S4: S1-S4
3. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004; 12: 708-715
4. Löhr A, du Bois A. Supportivtherapie in der gynäkologischen Onkologie - Teil 1. Geburts Frauenheilk 2003; 63: R113-R136
5. Taylor HG, Brown AW, ButlerWMet al. Treatment experience with nonsemnomous testicular cancer in patients with stage II and stage III disease. Cancer 1981; 48: 1110-1115
6. Osoba D, Zee B, Pater J et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and Symptom control committees of the National Cancer Institute of Canadian Clinical Trials Group. J Clin Oncol 1997; 15: 116-123 (Pubitemid 27020564)
7. Molassiotis A, Yam M, Yung H et al. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002; 10: 139-145
8. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. CIin J Oncol Nurs 1999; 3: 113-119
9. Bremer K. Individuelle Stufentherapie. DMW 1994; 119: 598-604
10. Junker A, Feyerabend T, Wiedemann GJ et al. Zytostatika- oder Strahlentherapie- induzierte Übelkeit und Erbrechen. Onkologe 2000; 3: 244-253
11. Hesketh PJ, Gralla RJ, du Bois A et al. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 1998; 6: 221-227
12. Koo WH, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7: 71-74
13. Stewart DJ, Dahouge S, Coyle D et al. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 1999; 17: 344-351
14. Loprinzi CL, Albrts SR, Christensen BJ et al. History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc 2000; 75: 303-309
15. Nolte MJ, Berkery R, Pizzo BA et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan Kettering Cancer Center. J Clin Oncol 1998; 16: 771-778